Avience Biomedicals lists 90% higher on NSE SME

Listing day snapshot

Avience Biomedicals Ltd (NSE SME: AVIENCE) debuted on the NSE SME Emerge platform on Thursday, 25 June 2026, with a sharp premium over its IPO price. The stock opened at ₹395.20 per share versus the issue price of ₹208, translating into a listing gain of about 90% for IPO allottees. Soon after the listing, the counter moved up another 5% to hit the upper circuit.

The upper circuit level was ₹414.95, where the stock remained locked. At ₹414.95, the stock traded at a 99.50% premium to the IPO price of ₹208. The move indicates strong secondary market demand on the first trading day, with the price immediately constrained by the SME segment’s circuit limits.

IPO price band and issue details

The IPO price band was fixed at ₹196 to ₹208 per share, and the final IPO price was ₹208. The face value of the equity shares was ₹10. The pricing outcomes and first-day trading levels placed the listing well above the top end of the band.

While the listing price sets the opening benchmark, investors typically track whether the stock sustains levels beyond the initial circuit-filtered move. In this case, the stock moved directly from the listing price to the upper circuit, leaving limited room for price discovery during the session.

Premium versus IPO price: what the numbers show

The headline listing gain was driven by the gap between the issue price and the first traded price. The opening at ₹395.20 marked a 90% jump over ₹208. The subsequent move to ₹414.95 represented a further 5% rise over the listing price, consistent with the reported upper circuit limit.

For IPO allottees, the day-one performance translated into gains ranging from the listing level to the circuit level, depending on the ability to transact. With the stock “locked” at the upper circuit, liquidity can be constrained, and execution may not be possible for all participants at the highest price.

Grey market premium (GMP) signal ahead of debut

Ahead of listing, the grey market premium (GMP) for Avience Biomedicals IPO was reported at +145. Based on that GMP, the indicated listing price was expected to be 69.71% higher than the IPO price. The actual opening at ₹395.20 represented a larger jump than the GMP-based indication cited in the provided details.

GMP is not an official market indicator, but it is commonly tracked by IPO watchers as a sentiment gauge. In this instance, the debut performance surpassed the specific GMP-based expectation mentioned.

Subscription response and demand indicators

The IPO received very strong investor participation, with an overall subscription reported at 385.32 times. Such a high oversubscription is often associated with sharp listing moves, particularly in SME offerings where the effective free float can be limited.

The information provided also states the IPO was open for subscription from 18 June to 22 June. Demand during the subscription period was cited as a factor that aligned with the strong debut.

Issue size, shares offered, and fund-raise target

As per the provided details, Avience Biomedicals aimed to raise ₹30.2 crore through the issuance of 14.53 lakh shares. Separately, the IPO size is also described as ₹30 crore in one of the excerpts, indicating the fund-raise was around ₹30 crore.

These figures give context on the scale of the offering and why the stock can see sharper moves on listing, especially when demand materially outstrips the supply of shares available for trading.

Impact on IPO allottees: lot-level illustration

The lot size was reported at 600 shares. With the stock reaching ₹414.95 on debut day, the provided details state a profit of ₹1,24,170 per lot for IPO investors. This computation is consistent with the narrative that gains approached 100% versus the IPO price by the time the stock hit the upper circuit.

Because the stock was locked at the upper limit, the ability to book gains depends on order matching and availability of buyers and sellers within the circuit-bound range.

Key facts table

Company contact details (as provided)

Avience Biomedicals has listed its email as info@avienbio.com and its website as www.avienbio.com.

What to watch after a circuit-locked debut

When an SME stock hits the upper circuit immediately after listing, the next few sessions typically determine how price discovery evolves once trading is not continuously capped. For investors tracking the counter, key variables include whether the stock continues to see sustained buying interest beyond the first day’s circuit move.

The debut data points are clear: the stock listed far above its issue price and quickly moved to the day’s cap. Any further updates would likely come through subsequent trading sessions as circuit filters allow more two-way participation.